Immix Biopharma, Inc. (IMMX)

US — Healthcare Sector
Peers: ZVSA  HEPA  AVRO  EFTR  CNSP  NAVB  SONN    FRLN  ENVB  CWBR  ELEV  OCEA 

Automate Your Wheel Strategy on IMMX

With Tiblio's Option Bot, you can configure your own wheel strategy including IMMX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IMMX
  • Rev/Share 0.0
  • Book/Share 0.323
  • PB 7.3993
  • Debt/Equity 0.1104
  • CurrentRatio 1.8028
  • ROIC -2.0475

 

  • MktCap 66626730.0
  • FreeCF/Share -0.4511
  • PFCF -4.9733
  • PE -3.3969
  • Debt/Assets 0.0532
  • DivYield 0
  • ROE -1.3002

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
IMMX
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
Immix Biopharma Attends FDA CEO Forum in Washington DC
IMMX
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D.

Read More
image for news Immix Biopharma Attends FDA CEO Forum in Washington DC
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
IMMX
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.

Read More
image for news Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
IMMX
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since the Company's most recent update.

Read More
image for news Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

About Immix Biopharma, Inc. (IMMX)

  • IPO Date 2021-12-16
  • Website https://www.immixbio.com
  • Industry Biotechnology
  • CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
  • Employees 18

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.